Hila Magen

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 17

Top Topics

Multiple Myeloma

Acute Lymphoblastic Leukemia

Top Venues

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Olga Ostrovsky, Katia Beider, Hila Magen, Merav Leiba, Ralph D Sanderson, Israel Vlodavsky, Arnon Nagler
Effect of HPSE and HPSE2 SNPs on the Risk of Developing Primary Paraskeletal Multiple Myeloma. Cells 12 (6) (2023)
Olga Ostrovsky, Katia Beider, Hila Magen, Merav Leiba, Ralph D Sanderson, Israel Vlodavsky, Arnon Nagler
Effect of HPSE and HPSE2 SNPs on the Risk of Developing Primary Paraskeletal Multiple Myeloma. Cells 12 (6) (2023)
Hila Magen, Abraham Avigdor, Lee Nevo, Shalev Fried, Amit Gibori, Einav G Levin, Yaniv Lustig, Eden Shkury, Galia Rahav
Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders. PloS one 18 (5) (2023)
Rivka Goldis, Batia Kaplan, Olga Lesya Kukuy, Michael Arad, Hila Magen, Efrat Shavit-Stein, Amir Dori, Avi Livneh
Diagnostic Challenges and Solutions in Systemic Amyloidosis. International journal of molecular sciences 24 (5) (2023)
Eyal Lebel, Efstathios Kastritis, Giovanni Palladini, Paolo Milani, Foteini Theodorakakou, Shlomzion Aumann, Noa Lavi, Liat Shargian, Hila Magen, Yael Cohen, Moshe E E Gatt, Iuliana Vaxman
Venetoclax in Relapse/Refractory AL Amyloidosis-A Multicenter International Retrospective Real-World Study. Cancers 15 (6) (2023)
Rivka Goldis, Batia Kaplan, Olga Lesya Kukuy, Michael Arad, Hila Magen, Efrat Shavit-Stein, Amir Dori, Avi Livneh
Diagnostic Challenges and Solutions in Systemic Amyloidosis. International journal of molecular sciences 24 (5) (2023)
Hila Magen, Abraham Avigdor, Lee Nevo, Shalev Fried, Amit Gibori, Einav G Levin, Yaniv Lustig, Eden Shkury, Galia Rahav
Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders. PloS one 18 (5) (2023)
Hila Magen, Abraham Avigdor, Lee Nevo, Shalev Fried, Amit Gibori, Einav G Levin, Yaniv Lustig, Eden Shkury, Galia Rahav
Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders. PloS one 18 (5) (2023)
Olga Ostrovsky, Katia Beider, Hila Magen, Merav Leiba, Ralph D Sanderson, Israel Vlodavsky, Arnon Nagler
Effect of HPSE and HPSE2 SNPs on the Risk of Developing Primary Paraskeletal Multiple Myeloma. Cells 12 (6) (2023)
Eyal Lebel, Efstathios Kastritis, Giovanni Palladini, Paolo Milani, Foteini Theodorakakou, Shlomzion Aumann, Noa Lavi, Liat Shargian, Hila Magen, Yael Cohen, Moshe E E Gatt, Iuliana Vaxman
Venetoclax in Relapse/Refractory AL Amyloidosis-A Multicenter International Retrospective Real-World Study. Cancers 15 (6) (2023)
Rivka Goldis, Batia Kaplan, Olga Lesya Kukuy, Michael Arad, Hila Magen, Efrat Shavit-Stein, Amir Dori, Avi Livneh
Diagnostic Challenges and Solutions in Systemic Amyloidosis. International journal of molecular sciences 24 (5) (2023)
Hila Magen, Abraham Avigdor, Lee Nevo, Shalev Fried, Amit Gibori, Einav G Levin, Yaniv Lustig, Eden Shkury, Galia Rahav
Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders. PloS one 18 (5) (2023)
Tamir Shragai, Hila Magen, Noa Lavi, Moshe E E Gatt, Svetlana Trestman, Miri Zektser, Chezi Ganzel, Osnat Jarchowsky, Tamar Berger, Tamar Tadmor, Merav Leiba, Katrin Hertzog-Tzarfaty, Netanel Horowitz, Michael Shapira, David Varssano, Yoav Berger, Shahar Frenkel, Mark Krauthammer, Irit Avivi, Efrat Luttwak, Yael C Cohen, null null
Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study. British journal of haematology (2022)
Hila Magen, Michal J Simchen, Shira Erman, Abraham Avigdor
Diagnosis and management of multiple myeloma during pregnancy: case report, review of the literature, and an update on current treatments. Therapeutic advances in hematology 13 (2022)
Ajai Chari, Paula Rodriguez-Otero, Helen McCarthy, Kenshi Suzuki, Vania Hungria, Anna Sureda, Aurore Perrot, Cyrille Hulin, Hila Magen, Shinsuke Iida, Vladimir Maisnar, Lionel Karlin, Ludek Pour, Dolly A Parasrampuria, Tara Masterson, Michele Kosh, Shiyi Yang, Maria Delioukina, Ming Qi, Robin Carson, Cyrille Touzeau
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. British journal of haematology 192 (5) (2020)
Meletios- Athanasios Dimopoulos, Sagar Lonial, Darrell White, Philippe Moreau, Katja Weisel, Jesus San-Miguel, Ofer Shpilberg, Sebastian Grosicki, Ivan Špička, Adam Walter-Croneck, Hila Magen, Maria-Victoria Mateos-Manteca, Andrew Belch, Donna Reece, Meral Beksac, Andrew Spencer, Heather Oakervee, Robert Z Orlowski, Masafumi Taniwaki, Christoph Röllig, Hermann Einsele, Morio Matsumoto, Ka Lung Wu, Kenneth C Anderson, Ying-Ming Jou, Alex Ganetsky, Anil K Singhal, Paul G Richardson
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood cancer journal 10 (9) (2020)
Jonathan L Kaufman, Meletios- Athanasios Dimopoulos, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, James Morton, P Joy Ho, Kihyun Kim, Naoki Takezako, Philippe Moreau, Heather J Sutherland, Hila Magen, Shinsuke Iida, Jin Seok Kim, H Miles Prince, Tara Cochrane, Albert Oriol, Nizar J Bahlis, Ajai Chari, Lisa O'Rourke, Sonali Trivedi, Tineke Casneuf, Maria Krevvata, Jon Ukropec, Rachel Kobos, Hervé Avet-Loiseau, Saad Z Usmani, Jesús San F Miguel
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. Blood cancer journal 10 (11) (2020)